Skip to main content

When the Dust Settles: Superpulsed Thulium Fiber Laser Versus MOSES Ho: YAG in Retrograde Intrarenal Surgery-A Systematic Review and Meta-analysis

In brief

Thulium laser yields 9% higher zero-fragment clearance than MOSES

Across seven studies involving 1,278 adults having kidney stone surgery, the thulium fiber laser was associated with a 9% higher rate of complete stone clearance than the MOSES-modulated holmium laser. Residual-fragment rates, operating time, and complications were similar, but most studies had serious risk of bias, so the apparent clearance advantage needs confirmation.

Journal
Current urology reports (Q1)
Published
20 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Saied Mohammed Saied Qasem, Ahmed Naji Ahmed Hassan, Mohamed L Ghanem, Mina Hany Foad Tawfik, Mohamed Khamis Abdullah El Masry, Aya Mohammad Abdel-Aleem, et al.
PMID
43058387
DOI
10.1007/s11934-026-01382-9

Why clinicians should know about it

  • Picked for Urology (paper of the day, 22 November 2026): Compares laser technologies for endoscopic kidney stone treatment

Abstract

PURPOSE OF REVIEW: Superpulsed thulium fiber laser (sTFL) and Lumenis MOSES pulse-modulated holmium: yttrium-aluminum-garnet (Ho: YAG) represent contemporary standards for retrograde intrarenal surgery (RIRS), operating through distinct photothermal and pulse-shape modulation mechanisms. Previous meta-analyses comparing these modalities have yielded conflicting conclusions largely due to pooling heterogeneous, non-modulated Ho: YAG generations and diverse surgical procedures. This study aims to systematically review and meta-analyze existing evidence evaluating sTFL exclusively against MOSES Ho: YAG regarding stone-free rates, operative efficiency, and safety in adults undergoing RIRS for stones ≤ 20 mm. RECENT FINDINGS: Of 1,290 records identified across five databases (PubMed, Scopus, Web of Science, ScienceDirect, and Europe PMC) through August 2026 (PROSPERO: CRD420261492557), 7 studies (3 randomized controlled trials and 4 comparative cohorts; 1,278 matched patients) met the inclusion criteria for the systematic review and meta-analysis. Meta-analysis showed that the sTFL cohort demonstrated a significantly superior absolute 0-mm stone-free rate compared to MOSES Ho: YAG (pooled RR 1.09, 95% CI 1.02-1.17, p = 0.014, I²=0.0%). However, clinically insignificant residual fragment (CIRF, ≤ 2-4 mm) rates were statistically equivalent between modalities both overall (pooled RR 1.06, 95% CI 0.93-1.21, I²=87.1%) and following the resolution of registry-driven heterogeneity (pooled RR 1.02, 95% CI 0.96-1.08, p = 0.59, I²=29.2%). Operative and lasing times were comparable between platforms. Both lasers exhibited equivalent overall complications (pooled RR 1.44, 95% CI 0.92-2.26) and severe adverse events (Clavien-Dindo ≥ III: RD 0.01, 95% CI - 0.00 to 0.02). Subgroup analyses revealed that elevated complication rates with sTFL were isolated to non-randomized, pure intrarenal cohorts (pooled RR 1.83, 95% CI 1.30-2.57) and follow-up ≥ 3 months (pooled RR 1.84, 95% CI 1.30-2.61), reflecting procedural confounders-such as ureteral access sheath underutilization-rather than inherent laser physics. Most studies were rated as having a high or serious risk of bias, primarily because of confounding and outcome measurement concerns. Leave-one-out sensitivity analyses supported the robustness of the findings. This systematic review highlights that while sTFL achieves superior absolute stone clearance (0 mm), both sTFL and MOSES Ho: YAG yield equivalent CIRF rates, operative efficiency, and safety profiles under standardized operative conditions. Relying on institutional availability and enforcing strict intrarenal pressure management may be valuable strategies for guiding clinical laser application.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.